April 1 (Reuters) – The European Medicines Agency recommended approving American biotech drug developer Amicus Therapeutics Inc’s experimental Fabry disease treatment.
The post Amicus gets positive EU regulator view for Fabry disease drug appeared first on NASDAQ.